Search

Author/Creator Van der Aa, Annegret

1. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Issue 10066 (21st January 2017)

Authors:
Vermeire, Séverine; Schreiber, Stefan; Petryka, Robert; Kuehbacher, Tanja; Hebuterne, Xavier; Roblin, Xavier; Klopocka, Maria; Goldis, Adrian; Wisniewska-Jarosinska, Maria; Baranovsky, Andrey; Sike, Robert; Stoyanova, Kremena; Tasset, Chantal; Van der Aa, Annegret; Harrison, Pille
Journal:
Lancet
Issue:
Volume 389:Issue 10066(2017)
Page Start:
266
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Issue 10162 (1st December 2018)

Authors:
Mease, Philip; Coates, Laura C; Helliwell, Philip S; Stanislavchuk, Mykola; Rychlewska-Hanczewska, Anna; Dudek, Anna; Abi-Saab, Walid; Tasset, Chantal; Meuleners, Luc; Harrison, Pille; Besuyen, Robin; Van der Aa, Annegret; Mozaffarian, Neelufar; Greer, Joy M; Kunder, Rebecca; Van den Bosch, Filip...
Journal:
Lancet
Issue:
Volume 392:Issue 10162(2018)
Page Start:
2367
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials. Issue 10 (31st August 2017)

Authors:
Vanhoutte, Frédéric; Mazur, Minodora; Voloshyn, Oleksandr; Stanislavchuk, Mykola; Van der Aa, Annegret; Namour, Florence; Galien, René; Meuleners, Luc; van 't Klooster, Gerben
Journal:
Arthritis & rheumatology
Issue:
Volume 69:Issue 10(2017)
Page Start:
1949
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. Issue 5 (17th November 2012)

Authors:
Westhovens, René; Keyser, Filip De; Rekalov, Dmytro; Nasonov, Evgeny L; Beetens, Johan; Van der Aa, Annegret; Wigerinck, Piet; Namour, Florence; Vanhoutte, Frédéric; Durez, Patrick
Journal:
Annals of the rheumatic diseases
Issue:
Volume 72:Issue 5(2013)
Page Start:
741
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P-178 Quality of Life Improvement Correlates with Clinical Remission in Patients with Active Crohn's Disease in Filgotinib Phase 2 FITZROY Study. (February 2017)

Authors:
Feagan, Brian; Vermeire, Severine; Schreiber, Stefan; Petryka, Robert; Kuehbacher, Tanja; Hebuterne, Xavier; Roblin, Xavier; Klopocka, Maria; Goldis, Adrian; Wisniewska-Jarosinska, Maria; Baranovsky, Andrei; Sike, Robert; Stoyanova, Kremena; Vyncke, Veerle; Meuleners, Luc; Tasset, Chantal; Harris...
Journal:
Inflammatory bowel diseases
Issue:
Volume 23(2017)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P046 HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JANUS KINASE 1 INHIBITOR FILGOTINIB IN ACTIVE CROHN'S DISEASE: RESULTS FROM FITZROY STUDY. (18th January 2018)

Authors:
Reinisch, Walter; D'Haens, Geert; Hertogh, Gert De; Van der Aa, Annegret; Etchevers K, Kim; Tasset, Chantal; Yun, Chohee; Serone, Adrian; Feagan, Brian; Sandborn, William J; Vermeire, Séverine
Journal:
Inflammatory bowel diseases
Issue:
Volume 24(2018)Supplement 1
Page Start:
S16
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. (1st May 2016)

Authors:
Namour, Florence; Galien, René; Van Kaem, Tim; Van der Aa, Annegret; Vanhoutte, Frédéric; Beetens, Johan; van't Klooster, Gerben
Journal:
British journal of clinical pharmacology
Issue:
Volume 82:Number 1(2016:Jul.)
Page Start:
139
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗